The tweet was deleted by the author.
But we saved everything 🙂.
Agenus will publish its second quarter 2026 financial results and provide a development update before the start of trading on Thursday, August 6.
The forthcoming report will offer investors and analysts an update on the company financial standing as well as its latest progress in development initiatives, including those related to immunotherapy. Investors tracking $AGEN are awaiting further details on how recent milestones may impact the outlook for the rest of the year.
View post on X Loading...
Recent updates include Agenus sharing 33 percent three-year overall survival and a 21.2 month median overall survival in refractory MSS mCRC patients treated with BOT plus BAL in a clinical trial. The company additionally announced new investigator-led studies of BOT plus BAL in neoadjuvant CRC and sarcoma at ESMO26, expanding its trial pipeline, according to an earlier release. These developments are among the updates expected to be discussed in the upcoming report.